top of page
Search
Press Release


Type 2 (T2)-targeted biologics have utility in the management of T2-low asthma, but more effective therapies are needed: Implications of EMBER study
The real-world study, “ Response to biologics along a gradient of T2 involvement in patients with severe asthma: a data-driven biomarker clustering approach ”, was recently published in The Journal of Allergy and Clinical Immunology: In Practice . Five biomarker clusters along a gradient of T2 involvement were identified using a data-driven approach instead of the pre-defined thresholds used in prior studies. Biologic use (Anti-IgE, Anti-IL5/5R and Anti-IL4Rα) was associated
Oct 15, 20253 min read


Cracking the Code: New ISAR Study Reveals How T2- and Non-T2 Inflammatory Pathways Predict Severe Asthma Exacerbations
A novel Bayesian Network analysis on the International Severe Asthma Registry (ISAR) has identified key clinical and biological pathways...
Jul 14, 20252 min read


Severe asthma biologic access criteria should consider long-term oral corticosteroid (LTOCS) users with low blood eosinophil counts (BEC): Implications of STAR study
The real-world study, “ Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in...
Jun 12, 20253 min read


Minimizing Steroid Burden in Severe Asthma: Real-World Data Demonstrate Biologics as a Game Changer
Drawing on data from over 5,600 severe asthma patients across real-world specialist and primary care settings in 22 countries, the SOLAR...
Jun 4, 20253 min read


New update from the International Severe Asthma Registry (ISAR)!
New real-world insights from the International Severe Asthma Registry (ISAR), spanning data from over 25 countries, have been featured in...
May 21, 20251 min read


Biologics for asthma prevent new-onset diabetes, major adverse cardiovascular events (MACE) as well as other oral corticosteroid (OCS)-related adverse events: Ground-breaking results from SOLAR II
The real-world SOLAR II study shows that biologic initiators had 18% lower risk of developing any oral corticosteroid (OCS)-related...
May 19, 20253 min read
bottom of page
